Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
penpulimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**Penpulimab + chemotherapy** is a combination drug regimen consisting of the anti–PD-1 monoclonal antibody penpulimab and platinum-based chemotherapy agents (cisplatin or carboplatin) plus gemcitabine. Penpulimab is a humanized IgG1 monoclonal antibody engineered to block programmed death receptor-1 (PD-1) on T cells, thereby preventing the binding of its ligands (PD-L1 and PD-L2), releasing immune “brakes” and allowing cytotoxic T-cell activity against cancer cells. The combination, approved by the FDA in 2025, is indicated for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). Chemotherapy agents (cisplatin/carboplatin and gemcitabine) induce DNA damage and cytotoxicity against rapidly dividing tumor cells, providing additive or synergistic effects with immunotherapy.
- Brand names
- penpulimab-kcqx
- Other names
- penpulimab + cisplatin + gemcitabinepenpulimab + carboplatin + gemcitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on penpulimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on penpulimab + chemotherapy.